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Abstract
Retinoschisin is encoded by the gene responsible for X-linked retinoschisis (XLRS), an early onset macular degeneration that
results in a splitting of the inner layers of the retina and severe loss in vision. Retinoschisin is predominantly expressed and
secreted from photoreceptor cells as a homo-oligomer protein; it then associates with the surface of retinal cells and
maintains the retina cellular architecture. Many missense mutations in the XLRS1 gene are known to cause intracellular
retention of retinoschisin, indicating that the secretion process of the protein is a critical step for its normal function in the
retina. However, the molecular mechanisms underlying retinoschisin’s secretion remain to be fully elucidated. In this study,
we investigated the role of the F-actin cytoskeleton in the secretion of retinoschisin by treating Weri-Rb1 cells, which are
known to secrete retinoschisin, with cytochalasin D, jasplakinolide, Y-27632, and dibutyryl cGMP. Our results show that
cytochalasin D and jasplakinolide inhibit retinoschisin secretion, whereas Y-27632 and dibutyryl cGMP enhance secretion
causing F-actin alterations. We also demonstrate that high concentrations of taxol, which hyperpolymerizes microtubules,
inhibit retinoschisin secretion. Our data suggest that retinoschisin secretion is regulated by the F-actin cytoskeleton, that
cGMP or inhibition of ROCK alters F-actin structure enhancing the secretion, and that the microtubule cytoskeleton is also
involved in this process.
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Introduction
Retinoschisin, also known as RS1, is a retinal-specific protein
encoded by the XLRS1 gene. Mutations in this gene cause X-linked
retinoschisis (XLRS), a leading cause of macular degeneration in
juvenile male patients [1]. The XLRS disease is characterized by
areas of schisis in the macula at the level of the nerve fiber and
ganglion cell layers – splitting that results in the formation of cystic
cavities in the central retina – and by a reduced b-wave amplitude in
the electroretinogram (ERG). These defects lead to impaired visual
signal processing and progressive vision loss with age [2].
Following the identification of the murine ortholog of XLRS1,
Xlrs1 or Rs1h [3,4], knockout mice deficient in this gene were
generated [5]. These mice showed disruption of the cell layer
architecture of the retina, irregular displacement of photoreceptor
cells to other retinal layers and increased extracellular space in the
region of photoreceptor ribbon synapses [5]. Subretinal delivery of
the Rs1h or XRLS1 gene into the knockout mice restored retinal
structure and function, indicating that retinoschisin plays an
important role in maintaining the proper architecture of the retina
and the integrity of the optic nerve fiber layer [6–8]. Other studies
also showed that retinoschisin serves as an anchor protein for the
maintenance of the organization of retinal synapses, especially the
photoreceptor synapses [9,10]. After assembly into disulfide-linked
multimers, retinoschisin interacts with proteins and phospholipids
at the surface of photoreceptors and other cell types forming multi-
molecular complexes with extracellular and cytoplasmic proteins.
These complexes may constitute the stabilizing scaffold for the
synapses [11–14].
Retinoschisin consists of a 23-amino acid N-terminal signal
peptide, a 41-amino acid retinoschisin- specific domain, which is
well conserved across species, and a 157-amino acid discoidin
domain flanked by two small segments of 39 and 5 amino acids
[11]. The signal peptide plays an essential role in guiding the
nascent retinoschisin polypeptide to the lumen of the ER and it is
subsequently removed by a signal peptidase. The folded peptide
assembles into a disulfide-linked homo-octameric complex prior to
secretion from cells [11]. It has been shown that Weri-Rb1
retinoblastoma cells express and secrete retinoschisin [15] and that
in adult mouse retina, retinoschisin is primarily secreted from the
inner segments of photoreceptors and, to a lesser extent, from
bipolar cells [9,10,13,15]. Wang et al. [16] described that missense
mutations in the signal peptide or discoidin domain lead to
intracellular retention of mutant retinoschisins, implicating the
corresponding mutated amino acids in the molecular mechanisms
underlying retinoschisin secretion. Moreover, it has been reported
recently that retinoschisin secretion is under circadian control in
chick retina [17]. However, little is known about the intracellular
regulatory factors that regulate retinoschisin transit and ultimately
its exit from the photoreceptor cells.
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The cytoskeleton, which consists of actin filaments and
microtubules, is a highly dynamic network actively involved in
many essential biological mechanisms such as those regulating
cellular structure, transport, cell movement, differentiation, and
signaling. Numerous studies have reported the requirement for an
intact cytoskeleton for the process of secretion [18,19]. In this
respect, Rho, one of the members of the small G-protein family,
and its effector, the Rho-associated kinase (ROCK) have been
shown to participate in the actin cytoskeleton assembly and
reorganization, and in a variety of other cellular processes
including cell contractility, cell-cell adhesion, migration and
invasion, phagocytosis, apoptosis and exocytosis [20]. Here we
show that depolymerization as well as hyperpolymerization of F-
actin inhibits retinoschisin secretion, resulting in the accumulation
of retinoschisin within cells. On the other hand, relaxing or
loosening the F-actin cytoskeleton by inhibition of ROCK
enhances retinoschisin secretion. Thus, our data define a dual
role for the F-actin cytoskeleton as a regulator of retinoschisin
secretion (inhibitor or enhancer) and demonstrate a critical
involvement of ROCK in this process. We also show that
disorganization of microtubules reduces retinoschisin secretion,
suggesting an active participation of this other component of the
cytoskeleton in the release of retinoschisin from retinal cells.
Results
Retinoschisin co-localizes with F-actin and the
microtubule cytoskeleton
In order to define whether F-actin is involved in retinoschisin
secretion, Triton X-100 permeabilized cells were stained with the
high-affinity probe for F-actin, Alexa Fluor 488-phalloidin,
and RS24-37. Weri-Rb1 cells are small, round cells with thin
cytoplasm and large nuclei; they grow in grape-like clusters [21].
Retinoschisin vesicles localized to their cytoplasm and cell
membrane, but not to their nuclei (Fig. 1, A and B). F-actin
was seen surrounding the nuclei and along the cells’ membranes
as well as in the cytoplasm (Fig. 1A). Partial co-localization of
retinoschisin with F-actin was observed in small, dot-like yellow
structures (Fig. 1A, enlarged areas 1, 2 and 3). We also double-
stained cells using antibodies against alpha tubulin and
retinoschisin. Microtubules were detected uniformly throughout
the cells as dense staining (Fig. 1B) and they partially co-localized
with retinoschisin (Fig. 1B, enlarged areas 4, 5 and 6). The co-
localization of retinoschisin with F-actin or microtubules suggests
that the cytoskeleton has the potential to regulate retinoschisin
secretion.
Cytochalasin D inhibits retinoschisin secretion
To investigate the role of F-actin in retinoschisin secretion, we
treated Weri-Rb1 cells with cytochalasin D, which depolymerizes
the F-actin cytoskeleton network. The dose-dependent effect of
this drug on cellular F-actin was visualized using Alexa Fluor 488
phalloidin (Fig. 2A). Concentrations up to 0.02 mM cytochalasin D
did not produce distinct morphological changes in the cells, which
displayed a smooth F-actin cytoskeleton such as that observed in
control, non-treated cells or in cells treated only with DMSO. At a
concentration of 0.2 mM cytochalasin D, cells were swollen and F-
actin was observed as small puncta, indicating fragmentation of
the F-actin cytoskeleton, but cells were still surrounded by thin F-
actin filaments. A higher concentration of cytochalasin D (2 mM)
caused more swelling and led to the aggregation of F-actin in
dense patches; in addition, the thin filaments surrounding the cells
were no longer seen. Overall, the changes in the F-actin
cytoskeleton of Weri Rb1 cells produced by cytochalasin D are
similar to those previously reported to occur in HEp-2 cells
subjected to cytochalasin D treatment [22]. To evaluate the effect
of the drug on retinoschisin secretion, Weri Rb1 cells were
incubated with cytochalasin D at the concentrations used in
Figure 2A, and the retinoschisin secreted into the respective
conditioned medium was estimated after Western blotting (Figs. 2B
and 2C). Our results indicated that DMSO, as well as 0.002 and
0.02 mM cytochalasin D, had no effect on cell morphology, the
actin cytoskeleton organization, and retinoschisin secretion (Figs. 2
A, B and C). Even when the F-actin cytoskeleton was fragmented
at 0.2 mM cytochalasin D, retinoschisin secretion was similar to
that observed with only DMSO present in the medium. On the
other hand, retinoschisin secretion was significantly decreased at
2 mM cytochalasin D, a concentration of the drug that caused
severe disruption of the F-actin cytoskeleton. This finding
indicated that F-actin, but not an intact F-actin cytoskeleton, is
required for retinoschisin secretion.
High concentrations of actin-disrupting drugs have previously
been shown to inhibit secretory or exocytotic events, while low
concentrations facilitate these events [23–25]. To determine
whether there was a biphasic response for retinoschisin secretion
after cytochalasin D treatment of cells and if so, which were the
critical concentrations of the drug that elicited these responses, we
examined the effects of nine different concentrations of cytocha-
lasin D between 0.02 to 2 mM (Fig. 2D); 5 other concentrations
between 0.002 and 0.02 mM did not change the secretion level
(data not shown). No biphasic response was observed within this
range of concentrations. However, our results indicated that
retinoschisin secretion decreased in a dose-dependent manner
between 0.5 and 2 mM cytochalasin D (Fig. 2D).
We next examined whether retinoschisin accumulated in the
cells exposed to cytochalasin D at concentrations of 0.002, 0.02
and 0.2 mM (Fig. 2E, left panel) and at 2 mM (Fig. 2E, middle
panel). Western blots of the proteins from the different cell lysates
using the RS24-37 antibody showed both the retinoschisin
monomer and dimer even after reduction by DTT, as was
previously observed with retinal samples [15,10], (Fig. 2E, right
panel). Pre-absorbing the RS24-37 antibody with the peptide that
was used to generate it corroborated its specificity: neither the
monomer nor the dimer bands were detected. As shown in
Figures 2E (2.160.4 –fold) and 2F, accumulation of retinoschisin
was observed within cells treated with 2 mM cytochalasin D.
We also investigated the reversibility of the cytochalasin D
effect. After exposure to DMSO and 1 mM or 2 mM cytochalasin
D for 72 hr, cells were cultured for another 72 hr in fresh medium
that had no drug in it. Removal of 1 mM cytochalasin D from the
cell culture restored the F-actin structure from dense patches to
small puncta and allowed thin filaments to surround again the cells
(Fig. 3A, right panel), a morphology very similar to that observed
in cells treated with 0.2 mM cytochalasin D (Fig. 2A). Further-
more, retinoschisin secretion was fully restored to the level
produced by DMSO (Figs. 3B and 3C, right panels). Removal
of 2 mM cytochalasin D from the medium restored the thin
filaments surrounding the cells, but dense patches still remained in
the cytoplasm (Fig. 3A, right panel). Although secretion was
restored, it was 20% lower than that of cells incubated only with
DMSO (Figs. 3B and 3C, right panels). These results indicate that
the effect of cytochalasin D on retinoschisin secretion is reversible
and that the degree of recovery is dose-dependent.
Jasplakinolide inhibits retinoschisin secretion
We next assessed the effects of jasplakinolide, a natural toxin
isolated from marine sponges that hyperpolymerizes the F-actin
cytoskeleton, on retinoschisin secretion. Weri-Rb1 cells treated
The Cytoskeleton Regulates Retinoschisin Secretion
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with 0.1 mM or 1 mM jasplakinolide were swollen and exhibited
irregular morphology that was completely different from the
smooth rounded shape of control cells or DMSO-treated cells
(Fig. 4A). F-actin in untreated cells exhibited smooth fluorescence
surrounding the cell surface. This fluorescence remained intact
following 72 h exposure to DMSO, 0.001 mM or 0.01 mM
jasplakinolide (Fig. 4A). On the other hand, 0.1 mM jasplakinolide
caused diffused and reduced fluorescence throughout the cell
cytoplasm and 1 mM jasplakinolide completely abolished phalloi-
din staining (Fig. 4A). This effect was the result of competitive
binding of jasplakinolide to F-actin, which blocks the binding sites
for phalloidin, as described by Bubb [26]. Retinoschisin secretion
was remarkably reduced by approximately 70% with 1 mM
jasplakinolide treatment (Figs. 4B and 4C). This concentration
caused a 2.960.8 -fold accumulation of retinoschisin in the cells
(Fig. 4D), suggesting that the F-actin cytoskeleton acts as a physical
barrier to retinoschisin secretion.
To determine whether the inhibitory effect of jasplakinolide on
retinoschisin secretion is reversible, the conditioned medium
containing 0.5 mM or 1.0 mM jasplakinolide was replaced with
toxin-free medium after 72 hr incubation and then the cells were
further cultured for another 72 hr. The effect of jasplakinolide on
retinoschisin secretion was completely reversed after removal of
the toxin: bound jasplakinolide was released from F-actin,
although the cell morphology and the F-actin structure were not
fully recovered (Figs. 5A, B, C).
Figure 1. Confocal microscopy images of Weri-Rb1 cells. (A) Cells were double-stained using the rabbit RS24-37 retinoschisin antibody
followed by Cy3-conjugated donkey-anti-rabbit IgG (RS1, red) and Alexa Fluor 488-phalloidin for F-actin (green). DAPI labeled the nuclei (blue). The
right image corresponds to the merged RS1 and F-actin images. The white squares limit Areas 1, 2 and 3 that have been zoomed in below. (B) Cells
were double-stained for retinoschisin with RS24-37 antibody followed by Alexa Fluor 488 goat anti-rabbit IgG (green) and alpha tubulin antibody
followed by Alexa Fluor 568 goat anti-mouse IgG (red). Nuclei were labeled with DAPI (blue). A merged image of the cells labeled for RS1 and alpha-
tubulin is at the right. Retinoschisin co-localized with the cytoskeleton proteins F-actin and alpha-tubulin as indicated by the arrowheads in the
enlarged images (1–6). Bar, 5 mm.
doi:10.1371/journal.pone.0020707.g001
The Cytoskeleton Regulates Retinoschisin Secretion
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Inhibition of ROCK changes F-actin structure and
enhances retinoschisin secretion
Since it is well known that members of the family of small G-
proteins regulate F-actin assembly [27], we investigated whether
inhibition of the Rho-associated kinase (ROCK) of Weri-Rb1 cells
by Y-27632, a highly specific Rho kinase inhibitor [28], could
affect retinoschisin secretion. The effects of Y-27632 on cell
morphology and the F-actin cytoskeleton were dose-dependent.
Weri-Rb1 cells treated with 20 mM Y-27632 showed dramatic
changes in morphology exhibiting spread cytoplasm and several
long protrusions of phalloidin-stained F-actin (Fig. 6A). Smaller
protrusions around cells were already seen at 10 mM Y-27632. At
these concentrations, F-actin fluorescence was reduced and non-
uniform throughout the cytoplasm. This is indicative of the F-actin
cytoskeleton destabilization, resulting in the loosening or relaxing
of F-actin fibers. Accordingly, treatment with 20 mM Y-27632
enhanced retinoschisin secretion by approximately 60% (Figs. 6B
and 6C) and there was no accumulation of retinoschisin observed
in cells (Fig. 6D). These data demonstrates that ROCK regulates
the secretion of retinoschisin.
Figure 2. Retinoschisin secretion into the conditioned medium is decreased by addition of cytochalasin D. (A) Effects of cytochalasin D
on cell morphology and F-actin cytoskeleton organization are dose dependent. Weri-Rb1 cells were cultured for 72 h in medium alone (untreated
control) and medium containing DMSO or the indicated concentrations of cytochalasin D. Cells were then fixed, labeled with Alexa Fluor 488-
phalloidin (green) and DAPI, and examined for changes in F-actin cytoskeleton organization. The upper row of pictures shows transmitted light
images and the lower row, fluorescent light images. Bar, 5 mm. (B) Retinoschisin secretion into the conditioned medium decreases by treatment of
cells with 2 mM cytochalasin D. Cells were treated as in (A) for 72 h. The medium for each condition was analyzed by Western blot using the RS24-37
antibody against retinoschisin. (C) Quantification of the intensity of each band on the Western blot in (B) (see MATERIALS AND METHODS). The data
are means 6 standard error of the mean (SEM) of three biological samples analyzed for each condition. (*) indicates that a p,0.05 was obtained for
the difference between 2 mM cytochalasin D- and DMSO-treated cells. (D) Retinoschisin secretion decreases in a dose-dependent manner by
treatment of cells with cytochalasin D at concentrations between 0.5 mM and 2 mM. Retinoschisin secretion was examined in the media of cells
treated with cytochalasin D concentrations in the range of 0.02 to 2 mM as in (B) and quantified as stated in (C). (E) Retinoschisin level in the whole cell
lysate increases with 2 mM cytochalasin D treatment. After 72 hr incubation in medium alone, medium containing DMSO or the indicated
concentrations of cytochalasin D (left and middle panels) the cells were collected and analyzed by Western blot. Both the monomer and dimer of
retinoschisin were detected in the retinal lysate (right panel). The intensities of the dimer and monomer bands for each sample were added and
normalized to GAPDH. The normalized results were compared to the values obtained for the cells incubated in medium containing only DMSO and
are shown as RS1/DMSO ratios. (F) Retinoschisin accumulates within cells treated with 2 mM cytochalasin D. Cells were treated with DMSO or 2 mM
cytochalasin D for 72 h. Cells were then fixed and incubated with RS24-37 antibody, followed by Alexa Fluor 488 goat anti-rabbit IgG. Nuclei were
labeled with DAPI.
doi:10.1371/journal.pone.0020707.g002
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DBcGMP enhances retinoschisin secretion
Several reports have shown that a cGMP-mediated pathway
regulates F-actin cytoskeleton by inhibiting the RhoA/ROCK
pathway [29–32]. DBcGMP, a permeable cGMP analogue, was
employed to examine the involvement of cGMP in retinoschisin
secretion from Weri Rb1 cells. At 1 mM DBcGMP, F-actin
showed small protrusions around cells. The protrusions were
extended at 2 mM DBcGMP and the phalloidin staining was
reduced in the cytoplasm (Fig. 7A). These effects are similar to
those produced by Y-27632 on Weri Rb1 cells (Fig. 6A). As seen in
Figures 7B and 7C, treatment with 2 mM DBcGMP almost
doubled retinoschisin secretion, suggesting the involvement of
cGMP in this process.
The microtubule-hyperpolymerizing reagent, taxol,
suppresses retinoschisin secretion
Since the partial co-localization of retinoschisin and microtu-
bules was observed in Figure 1, we investigated the involvement of
the microtubule cytoskeleton in retinoschisin secretion using taxol,
a modifier of microtubules that facilitates their hyperpolymeriza-
tion [33]. At a concentration of 1 mM taxol, Weri Rb1 cells
showed a thickened mass of microtubules, and at 5 mM taxol,
disorganized bundles of microtubules were observed (Fig. 8A).
Cells treated with 10 mM taxol were compressed and their
microtubules were disorganized further. These observations
indicated that the effect of taxol on the microtubule cytoskeleton
was dose-dependent. Treatment of cells with 0.5 mM, 1 mM, or
Figure 3. The effect of cytochalasin D on retinoschisin secretion is reversible. (A) F-actin cytoskeleton organization visualized with Alexa
Fluor 488-phalloidin (green). Duplicate cell samples were treated with DMSO or 1 mM and 2 mM cytochalasin D (CyD) for 72 hr. One of the sets of cells
was then fixed and labeled for F-actin (left panel). The conditioned medium of the duplicate set of samples was replaced by fresh medium without
DMSO (DMSORmedium) or cytochalasin D (CyD 1 or 2 mMRmedium) in it. Cells were incubated for another 72 hr in the fresh medium, fixed and
labeled with Alexa Fluor 488-phalloidin. (B) Western blot of proteins from the medium of each sample described in (A). Retinoschisin was detected
using the RS24-37 antibody. (C) Quantification of the intensity of each band on the Western blot in (B) (see MATERIALS AND METHODS). The data are
means6 SEM of three different biological samples for each condition. *: p,0.05 was obtained for the difference between 1 mM or 2 mM cytochalasin
D- and DMSO-treated cells.
doi:10.1371/journal.pone.0020707.g003
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5 mM taxol resulted in 50% reduction of retinoschisin secretion
accompanied by accumulation of the protein within the cells
(Figs. 8B and 8C). Incubation with 10 mM taxol reduced even
more (approximately by 70%) secretion and the retinoschisin
monomer was no longer present in the cells (Fig. 8D). These results
suggest that the microtubule cytoskeleton also plays a role in
retinoschisin secretion.
Discussion
Ultrastructural studies of actively secreting cells have demon-
strated the presence of extensive F-actin networks in their
cytoplasm and a dense F-actin cortex under their plasma
membrane [34]. This F-actin zone has been shown to be an
obstacle that impedes exocytosis of secretory granules at the
plasma membrane of neurons, neuroendocrine, endocrine,
exocrine and hematopoietic cells [35]. Therefore, vesicular
trafficking would require an active process of F-actin disassembly
to mediate movement through cortical actin. However, it has been
reported that the F-actin network plays both inhibitory and
facilitatory roles in exocytosis [24]. On one hand, it acts as a
physical barrier, preventing granule access to their appropriate
docking and fusion sites on the plasma membrane, as proved by
demonstrating that pharmacological disruption of F-actin en-
hanced basal and stimulus coupled exocytosis [34,36,37]. But on
the other hand, the F-actin cytoskeleton also contributes to
exocytosis, as shown by reduced exocytosis during pharmacolog-
ical alteration of F-actin in some cell types [38–40]. Furthermore,
active cytoskeletal rearrangements have been shown to accompany
many vesicle transport and fusion events in a variety of cell systems
Figure 4. Retinoschisin secretion into the conditioned medium is decreased by addition of jasplakinolide. (A) Effects of jasplakinolide
on cell morphology and F-actin cytoskeleton organization. Weri-Rb1 cells were cultured in medium alone (untreated control) and medium containing
DMSO or the indicated concentrations of jasplakinolide for 72 h. Cells were then fixed and labeled with Alexa Fluor 488-phalloidin (green). The upper
row of pictures shows transmitted light images and the lower row, fluorescent light images. Bar, 5 mm. (B) Western blot of proteins in the conditioned
media of cells treated with DMSO or the indicated concentrations of jasplakinolide for 72 h using the RS24-37 antibody. As seen, retinoschisin
secretion into the conditioned medium is decreased by 1 uM jasplakinolide. (C) Quantification of the intensity of each band in the Western blot in (B)
(see MATERIALS AND METHODS). The data are means 6 SEM of three different biological samples for each condition. *: p,0.05 was obtained for the
difference between 1 mM jasplakinolide- and DMSO-treated cells. (D) Restinoschisin accumulates inside cells treated with 1 mM jasplakinolide. After
72 hr incubation in medium alone, medium containing DMSO or the indicated concentrations of jasplakinolide, cells were collected and analyzed by
Western blot. The intensities of the dimer and monomer bands for each condition were added and normalized to GAPDH. The normalized values
were then compared to that of DMSO-treated cells and are shown as RS1/DMSO ratios. (E) Retinoschisin accumulates within cells treated with 1 mM
jasplakinolide. Cells were treated with DMSO or 1 mM jasplakinolide for 72 h. Cells were then fixed and incubated with RS24-37 antibody followed by
Alexa Fluor 488 goat anti-rabbit IgG. Nuclei were labeled with DAPI.
doi:10.1371/journal.pone.0020707.g004
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[41,42]. Our findings indicating that retinoschisin secretion is
inhibited by actin depolymerizing (cytochalasin D) or hyperpo-
lymerizing (jasplakinolide) drugs are consistent with secretion
results reported for other proteins and cells in the literature
[38,40]. In addition, we observed accumulation of retinoschisin in
Weri Rb1 cells treated with 2 mM cytochalasin D or 1 mM
jasplakinolide. These results indicate that the F-actin cytoskeleton
contributes to retinoschisin secretion but can also act as a barrier
for its secretion.
It is important to note that low concentrations of cytochalasin D
(0.2 mM) and jasplakinolide (0.1 mM) had no effect on retinoschisin
secretion despite some changes exhibited on the F-actin cytoskel-
eton, whereas high concentrations of these drugs (2 mM and 1 mM,
respectively) caused dramatic alterations of the F-actin cytoskel-
Figure 5. The effect of jasplakinolide on retinoschisin secretion is reversible. (A) The F-actin cytoskeleton was visualized by Alexa Fluor 488-
phalloidin (green). Duplicate cell samples were treated with DMSO or 0.5 mM and 1.0 mM jasplakinolide (Jas) for 72 h and then one set was fixed and
labeled for F-actin (left panel). The conditioned medium of the other set of samples was replaced by fresh medium without DMSO (DMSORmedium)
or jasplakinolide (Jas 0.5 mM or 1.0 mMRmedium) in it. Cells were incubated for another 72 h in the fresh medium, fixed, and labeled with Alexa Fluor
488-phalloidin. (B) Western blot of proteins from the medium of each sample described in (A). Retinoschisin was detected using the RS24-37
antibody. (C) Quantification of the intensity of each band on the Western blot in (B) (see MATERIALS AND METHODS). The data are means 6 SEM of
three different biological samples for each condition. *: p,0.05 was obtained for the difference between 0.5 mM or 1 mM jasplakinolide- and DMSO-
treated cells.
doi:10.1371/journal.pone.0020707.g005
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Figure 6. Retinoschisin secretion into the conditioned medium is increased by the ROCK kinase inhibitor, Y-27632. (A) Effects of
Y-27632 on cell morphology and F-actin cytoskeleton organization. Weri-Rb1 cells were cultured in medium alone (untreated control) or the indicated
concentrations of Y-27632 for 72 h. Cells were then fixed and labeled with Alexa Fluor 488-phalloidin (green). The upper row of pictures shows
transmitted light images and the lower row, fluorescent light images. Bar, 5 mm. (B) Retinoschisin from the conditioned media of cells treated as in (A)
was detected on a Western blot using the RS24-37 antibody. As seen, retinoschisin secretion into the conditioned medium is increased at 20 mM
Y-27632. (C) Quantification of the intensity of each band on the Western blot from (B) (see MATERIALS AND METHODS). The data are means6 SEM of
three different biological samples for each condition. *: p,0.05 was obtained for the difference between 20 mM Y-27632-treated and untreated cells.
(D) The level of retinoschisin in the lysates of whole cells treated with the concentrations of Y-27632 used in (B) does not change. After 72 hr
incubation in medium alone or medium containing the indicated concentrations of Y-27632, cells were collected and their retinoschisin was analyzed
on a Western blot using the RS24-37 antibody. The band intensities of the dimer and monomer for each condition were added and normalized to
GAPDH. The normalized values for treated and untreated cells were compared and are shown as RS1/control ratios.
doi:10.1371/journal.pone.0020707.g006
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eton and suppressed retinoschisin secretion. Moreover, we showed
that the effects of cytochalasin D and jasplakinolide on the
secretion process were fully reversible upon removal of these drugs
from the culture medium, even when complete restoration of the
F-actin cytoskeleton was not achieved. These observations imply
that F-actin must be present for retinoschisin secretion to occur.
Figure 7. DBcGMP enhances retinoschisin secretion and modifies F-actin localization. (A) Effects of DBcGMP on the F-actin cytoskeleton.
Weri-Rb1 cells were cultured with medium alone (untreated control) or the indicated concentrations of DBcGMP for 72 h. Cells were then fixed and
labeled with Alexa Fluor 488-phalloidin (green). Note the F-actin protrusions in cells treated with 1 mM and 2 mM DBcGMP. Bar, 5 mm. (B) Retinoschisin
secretion into the medium increases with the three concentrations of DBcGMP used to treat the cells for 72 h, as seen on the Western blot of the media
samples reacted with the RS24-37 antibody. (C) Quantification of the retinoschisin bands on the Western blot in (B) (see MATERIALS ANDMETHODS). The
data are means 6 SEM of three different biological samples for each condition. Retinoschisin levels in the culture medium of cells treated with the
different concentrations of DBcGMP are all higher than in the medium of untreated cells, but the results are statistically significant only for the cells
treated with 1 and 2 mM DBcGMP. *: p,0.05 was obtained for the difference between DBcGMP-treated and untreated cells.
doi:10.1371/journal.pone.0020707.g007
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Figure 8. Retinoschisin secretion into the conditioned medium is decreased by addition of taxol. (A) Effects of taxol on cell morphology
and microtubule organization. Weri-Rb1 cells were cultured with medium containing DMSO or the indicated concentrations of taxol for 72 h. Cells
were then fixed and labeled with an a tubulin antibody (red). The upper and lower rows of pictures show transmitted light images and fluorescent
light images, respectively. The microtubule cytoskeleton of cells shows bundles after treatment with 5 mM and 10 mM taxol. Bar, 5 mm. (B) Cells were
treated with the indicated concentrations of taxol for 72 h and retinoschisin in the conditioned media was analyzed on Western blots using the RS24-
37 antibody. Retinoschisin secretion into the medium decreases in a dose-dependent manner between 0.5 mM and 10 mM taxol. (C) Quantification of
the intensity of the bands from the Western blot in (B) (see MATERIALS AND METHODS). The data are means 6 SEM of three different biological
samples for each condition. *: p,0.05 was obtained for the differences between 0.5 mM–10 mM taxol-treated and DMSO-treated cells. (D) After 72 hr
incubation in medium containing DMSO or the indicated concentrations of taxol, cells were collected and analyzed by Western blot using the RS24-
37 antibody. The intensities of the bands corresponding to the dimer and monomer of retinoschisin at each taxol concentration were added and
normalized to GAPDH. The normalized values were compared to that of cells treated with DMSO and shown as RS1/DMSO ratios. Retinoschisin
accumulates inside the cells exposed to taxol at concentrations between 0.5 mM and 10.0 mM.
doi:10.1371/journal.pone.0020707.g008
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Small GTPases of the Rho family are important regulators of
many motile responses that involve the actin cytoskeleton and/or
microtubule network [20]. Three main classes of Rho GTPases,
Rho, Rac, and Cdc42, play key roles in vesicular secretion by
regulating actin cytoskeletal dynamics [43,44]. Furthermore, studies
on different cell types have shown that inhibition of downstream
effectors of Rho GTPases also contribute to vesicular trafficking by
controlling the organization of the F-actin cytoskeleton. For
example, inhibition of Rho’s downstream effector, Rho-associated
kinase (ROCK), and thereby of the Rho-ROCK signaling pathway,
induces actin depolymerization and improves glucose-stimulated
insulin secretion of primary pancreatic B-cells [45]. In mast cells,
Rho controls F-actin disassembly and secretion [46]. In addition,
late steps of exocytosis are affected as a consequence of actin
filaments severed by gelsolin, a downstream effector of Rac [47]. In
rabbit parietal cells, any treatment that inhibits Rho augments acid
secretion, whereas those that activate Rho inhibit secretion via site-
specific regulation of actin microfilaments [48]. In this study, we
demonstrated that retinoschisin secretion was facilitated by the
loosening or relaxing of the F-actin cytoskeleton through inhibition
of ROCK with 20 mM Y-27632, confirming that the F-actin
cytoskeleton functions as a physical barrier for retinoschisin
secretion, as also demonstrated before by the accumulation of
retinoschisin within cells treated with jasplakinolide.
Interestingly, we here demonstrate the involvement of cGMP in
retinoschisin secretion. cGMP is an important second messenger
that regulates a variety of intracellular activities, such as the
contraction of cardiac and smooth muscle, the immune cell
response, synaptic transmission, and secretion [49–51]. In retinal
photoreceptors, cGMP mediates phototransduction, influx of
Ca2+, transmitter release, and exocytosis [52–54]. In this paper,
we show that DBcGMP, a permeable analogue of cGMP, altered
F-actin structure and enhanced retinoschisin secretion, causing
similar results to those obtained when Weri RB1 cells were treated
with the ROCK inhibitor Y-27632. In fact, a cGMP-mediated
pathway is known to inhibit RhoA/ROCK and control cytoskel-
eton dynamics [29,31], suggesting that the RhoA/ROCK
pathway might regulate retinoschisin secretion. This finding
unveils a new function for cGMP in retina.
Microtubules are dynamic cytoskeletal components that are
important for the maintenance of cell shape and polarity, in
secretion, signaling, migration, and other cellular processes [55].
Taxol is a potent inhibitor of eukaryotic cell proliferation. It binds
reversibly along the surfaces of microtubules, and at high
concentrations (1–20 mM) it enhances microtubule polymerization
and also induces the formation of extensive bundles of microtu-
bules in cells. In human cancer cells, low concentrations of taxol
(,0.1 mM) block or slow mitosis and suppress microtubule
dynamic instability and treadmilling without changing the overall
microtubule polymer mass [55]. In this study, a low concentration
of taxol (0.1 mM) had no effect on the microtubule network of
Weri Rb1 cells or on retinoschisin secretion. In contrast,
concentrations of taxol higher than 1 mM resulted in dramatic
alterations of microtubule structure, such as thickened microtu-
bules and disorganized bundles, and caused a decrease in
retinoschisin secretion. These results are consistent with those of
other studies that showed that taxol inhibits microtubule-
dependent secretion or vesicle transport in cultured cells [56,57].
Since it has been described that microtubules act as tracks to
transport vesicles [58], it is possible that the taxol-thickened and
bundled microtubules that we observe may not be able to function
as tracks, leading to the reduction of retinoschisin secretion and
accumulation of the protein in Weri Rb1 cells. Thus, our
experiments suggest that an intact microtubule cytoskeleton is
required for retinoschisin secretion, and that microtubules may
indeed act as tracks for retinoschisin leading the protein to the
cells’ plasma membranes. However, we observed that 0.5 mM
taxol suppressed retinoschisin secretion without significant micro-
tubule alteration. A reasonable explanation for this could be that
taxol induces fragmentation of the trans-Golgi network (TGN), as
previously reported [59], and thus it may disturb the sorting or
packaging of proteins at the TGN with a concomitant decrease in
their secretion.
In summary, we showed that retinoschisin secretion is highly
regulated by cytoskeleton structures and by a signaling pathway: a
dual function of the F-actin cytoskeleton can both hinder and
mediate retinoschisin secretion, a cGMP-mediated inhibition of
ROCK is possibly involved in the regulation of this process and
the microtubule cytoskeleton is required for retinoschisin secretion
to occur, as depicted in Figure 9.
Recently it was demonstrated that retinoschisin secretion is
under circadian control [17] and that L-type voltage-gated
calcium channels (L-VGCCs) are involved in this control [60].
Interestingly, it has been reported that one of the small GTPases,
Rab3A, influences circadian rhythms in the mouse [61]. Evidence
implicating Rab3A in exocytosis has also been described for
different cells including chromaffin cells, PC12 cells, insulin
secreting cells, and pancreatic exocrine cells [35]. It is possible
that Rab3A may play a key regulator role in the circadian control
of retinoschisin secretion. Moreover, a subset of Rab and SNARE
proteins, which are implicated in vesicle trafficking and membrane
fusion, were identified in retina outer segments by a tandem mass
spectrometry-based proteomics approach [62]. Further studies are
needed to define the function of various small GTPases and
proteins involved in cellular signal transduction as regulators of
intracellular cytoskeleton dynamics. The results of these studies
will give greater insight into the molecular mechanisms underlying
retinoschisin secretion and eventually lead to the development of
treatment strategies for XLRS.
Materials and Methods
Secretion experiments and chemical reagents used
Weri-Rb1 human retinoblastoma cells [21] were obtained from
the American Type Tissue Culture Collection (Manassas, VA) and
cultured in RPMI-1640 medium (Thermo Scientific HyClone,
Logan, UT) supplemented with 10% fetal bovine serum (Hyclone)
at 37uC in 5% CO2. For secretion experiments, cells were plated
on six-well dishes (36106 cells per well) coated with poly-D-lysine
(0.2 mg/ml, Sigma-Aldrich, St. Louis, MO) and fibronectin (5 mg/
ml, Sigma-Aldrich). Cells were grown in 1 ml of medium
containing different concentrations of drugs. Drugs used were:
cytochalasin D and jasplakinolide [EMD4 Biosciences (Calbio-
chem, San Diego, CA)], and paclitaxel (taxol), Y-27632 and
dibutyryl cGMP (DBcGMP) (Sigma-Aldrich). Cytochalasin D,
jasplakinolide, and taxol were dissolved in dimethylsulfoxide
(DMSO). DMSO concentration did not exceed 1% in the
cultures. Cells were cultured for 72 h and their protein extracts
were subjected to Western blot analysis using RS24-37, an affinity
purified rabbit polyclonal antibody previously generated against a
synthetic peptide corresponding to amino acid residues 24-37 of
retinoschisin [15] (ProSci Inc., San Diego, CA).
Western blot analysis
After 72 h incubation with each drug, conditioned media and
cells were collected separately. The conditioned media were
filtered using an Ultrafree-MC filter (0.1 mm pore size, Millipore,
Billerica, MA) to remove cell debris. Cells were incubated on ice
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for 15 min with lysis buffer containing 50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
1 mM PMSF, and Halt Protease Inhibitor Cocktail (Thermo
Scientific Pierce, Rockford, IL) and then the cell debris was
cleared by centrifugation at 10,000 g for 20 min at 4uC. The
filtered conditioned media or the cell lysates were incubated in a
denaturing solution (100 mM Tris, pH 6.8, 1% SDS, 10%
glycerol, and 90 mM DTT) at room temperature for at least 1 h
and resolved on 10% polyacrylamide SDS gels (BioRad, Hercules,
CA). Proteins were electroblotted onto PVDF membranes
(BioRad) in transfer buffer (50 mM Tris, 380 mM glycine, and
20% methanol) overnight at 4uC. The membranes were blocked
using 3% nonfat milk in TBST (50 mM Tris, pH 7.4, 500 mM
NaCl, and 0.1% Tween 20) and incubated with RS24-37 (1:400)
or with monoclonal anti-GAPDH (1:10,000, clone 6C5, Applied
Biosystems, San Diego, CA) containing 3% BSA in TBST, for at
least 1 hr. After incubation with antibodies, the membranes were
washed three times in TBST, incubated with an alkaline
phosphatase-conjugated goat-anti-rabbit IgG or horse-anti-mouse
IgG, respectively (Vector Laboratories, Burlingame, CA) for 1 h,
and washed three times in TBST. Bands were detected on
Amersham Hyperfilm-MP (GE Healthcare UK Ltd., Piscataway,
NJ) by using the DuoLux chemiluminescence substrate (Vector
Laboratories). The density of the bands was quantified using a
ChemiImager 5500 (Alpha Innotech, San Leandro, CA). The
amount of retinoschisin in the culture medium of the control
sample (RPMI 1640 medium or RPMI 1640 medium containing
only DMSO) was used as baseline and it was measured in every
blot of each experiment. The level of retinoschisin in each
conditioned medium was estimated as the percent of the difference
from the baseline on the same blot. The density of retinoschisin
from cells was normalized to that of GAPDH on the same blot.
Paired t-test (two-tailed) was employed for comparisons between 2
groups. A value of p,0.05 was considered statistically significant.
Immunocytochemistry
Cells were plated onto cover slips coated with poly-D-lysine
(0.2 mg/ml) and fibronectin (5 mg/ml) in twelve-well dishes
(26105 cells per well). After 72 h incubation with each drug, cells
were washed twice with PBS, fixed with 4% paraformaldehyde for
10 min at room temperature and blocked by incubation for 1 h in
PBS containing 1% BSA, 5% normal serum, and 0.1% Triton X-
100. Primary antibodies used were RS24-37 (1:50) and monoclo-
nal anti-alpha tubulin (1:250; DM1A, eBioscience, San Diego,
CA). Secondary antibodies used were indocarbocyanine (Cy3)-
conjugated donkey-anti-rabbit IgG (for staining retinoschisin red,
1:200, Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA); Alexa Fluor 488 goat anti-rabbit IgG (for staining
retinoschisin green) and Alexa Fluor 568 goat anti-mouse IgG
(for staining tubulin red), both at dilutions of 1:1000 (Invitrogen-
Figure 9. Summary diagram for the roles of the F-actin and microtubule cytoskeletons in retinoschisin secretion. Different
pharmacological treatments of Weri-Rb1 cells showed that: The F-actin depolymerizing drug cytochalasin D causes fragmentation of F-actin and
inhibits secretion of retinoschisin in a dose-dependent manner at concentrations higher than 0.5 mM. At 2 mM cytochalasin D, this inhibition of
secretion results in a 2.1-fold accumulation of retinoschisin within the cultured cells. The natural toxin Jasplakinolide (1 mM) hyperpolymerizes F-actin
and results in the reduction of retinoschisin secretion and its 2.9-fold accumulation within the cells. Inhibition of ROCK using 20 mM Y-27632 or
treatment with 2 mM DBcGMP relaxes the F-actin cytoskeleton and almost doubles retinoschisin secretion. Hyperpolmerization of microtubules by
taxol results in disorganized microtubule bundles that reduce retinoschisin secretion. The solid arrows indicate increased retinoschisin secretion and
the dotted arrows, decreased secretion.
doi:10.1371/journal.pone.0020707.g009
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Molecular Probes, Carlsbad, CA). F-actin was visualized by
staining with Alexa Fluor 488-phalloidin (Invitrogen-Molecular
Probes, 1:100). Cells were washed with PBS containing 0.1%
Tween 20 (4 times, 5-min each) following incubation with primary
and secondary antibodies. After immunostaining, samples were
mounted on slides using Biomeda Gel-Mount medium (Electron
Microscopy Sciences, Hatfield, PA) and analyzed by confocal
microscopy (Leica TCS SP2 microscope, Leica Microsystems,
Germany) or a fluorescence microscope (Axioplan, Carl Zeiss,
Germany).
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